What do systematic reviews say?

Edaravone plus corticosteroids vs corticosteroids

The review found no eligible studies for this question.

• Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: bevacizumab vs placebo

The review found no eligible studies for this question.

• Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Amifostine vs no treatment/placebo

Amifostine showed no clear difference in quality of life compared with no treatment/placebo; GRADE not reported.

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes

  End of RT; up to 3 months postRT
  MD 0.52 [-0.02, 1.06]
  1 study · 233 participants
  GRADE not reported

Antiseptic mouthrinse vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No quality of life data were reported.
  0 studies
  No studies found

Bethanechol vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No data on either quality of life or other oral related symptoms were reported.
  0 studies
  No studies found

Chinese medicine vs no treatment/placebo

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes

  End of intervention to 3 months postRT
  Insufficient evidence to determine any effect on quality of life (Lin 2014; Analysis 6.5)
  1 study
  GRADE not reported

Amifostine (intravenous) vs Amifostine (subcutaneous)

The review found no eligible studies for this question.

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No data on either quality of life or other oral related symptoms were reported.
  0 studies
  No studies found

Escalated BEACOPP vs chemotherapy including ABVD

The review found no eligible studies for this question.

• Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interferon‐α combined with targeted therapies vs standard targeted therapies

The review found no eligible studies for this question.

• Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dexamethasone vs placebo

The review found no eligible studies for this question.

• Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy,… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Venalot Depot (coumarin plus troxerutin) vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No data on either quality of life or other oral related symptoms were reported.
  0 studies
  No studies found

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes

  End of RT and 6, 12, 18, 24 months postRT
  No significant differences between the three treatment arms (Jellema 2006)
  1 study
  GRADE not reported

Bethanechol vs Artificial saliva

The review found no eligible studies for this question.

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No data on either quality of life or other oral related symptoms were reported.
  0 studies
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention may leads to higher quality of life (low certainty).

• Chemotherapy versus best supportive care for extensive small cell lung cancer 2013 · Cochrane Headline outcomes only
  RR 2.18 [0.05, 0.25]
  1 study · 141 participants
  Low

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antihypertensive drug therapy vs placebo

• Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 15795 participants
  Very low

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found